Keywords: boston, sci, taxus, favorable, tlr, rate, vs
Boston Sci's Taxus favorable TLR rate vs J&J's Cypher
Article | 22 January 2007
US vascular devices maker Boston Scientific says that an independent study demonstrates that its Taxus paclitaxel-eluting stent exhibited a lower ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
